Ironwood Pharmaceuticals (IRWD) Operating Leases (2019 - 2025)
Ironwood Pharmaceuticals (IRWD) has disclosed Operating Leases for 7 consecutive years, with $9.9 million as the latest value for Q4 2025.
- Quarterly Operating Leases fell 19.78% to $9.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.9 million through Dec 2025, down 19.78% year-over-year, with the annual reading at $9.9 million for FY2025, 19.78% down from the prior year.
- Operating Leases hit $9.9 million in Q4 2025 for Ironwood Pharmaceuticals, down from $10.5 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $19.9 million in Q1 2021 to a low of $9.9 million in Q4 2025.
- Historically, Operating Leases has averaged $15.2 million across 5 years, with a median of $15.3 million in 2023.
- Biggest five-year swings in Operating Leases: dropped 8.24% in 2021 and later decreased 19.78% in 2025.
- Year by year, Operating Leases stood at $18.5 million in 2021, then fell by 10.2% to $16.6 million in 2022, then fell by 12.39% to $14.5 million in 2023, then dropped by 15.4% to $12.3 million in 2024, then decreased by 19.78% to $9.9 million in 2025.
- Business Quant data shows Operating Leases for IRWD at $9.9 million in Q4 2025, $10.5 million in Q3 2025, and $11.1 million in Q2 2025.